Development of domestic COVID-19 vaccines has come to a standstill before entering the final stages - the phase 3 trials. Cellid, which had shown the fastest progress in development, is planning to reenter phase 1 trials with an improved version of its vaccine. Due to such changes, the industry has a negative outlook on the commercialization of domestic vaccines by the first half of next year.

According to the Ministry of Food and Drug Safety on the 26th, there are currently 10 candidate COVID-19 vaccines in clinical trials in Korea. The Phase 1 clinical trial for HK Inno.N’s recombinant vaccine, ‘IN-B009,’ was approved on the 22nd to increase the count to ten. 5 are recombinant vaccines, 3 are DNA vacc